There are several dots which you connect that do perhaps have merit but still suspect at this point, without verification.
It is your conclusion that baffles me ,
'will be more that willing to buy these assets at very favorable prices', i don't think anyone is interested in purchasing any 'assets' of ASR because i see little value there. Also, i do not think Bayer will be buying much more NDD product.
You seem to think otherwise, why? Dog
News 
Market Data 
Discover 
AI
